impactbiomedinc.com (IBO) - Dhuwit awis perusahaan

IBO (Impact BioMedical Inc) - tandha merek perusahaan

Commercialization prospects for the patent developments of Impact BioMedical Inc (IBO) remain distant, and current costs are already priced in. An opaque ownership structure and weak management negatively impact capitalization. This chart on GURU.Markets displays the cash on hand metric, where the value stands at 0.00. Meanwhile, the holding company is effectively scaling the business through intellectual property management without inflating headcount.

IBO - Dana dhuwit perusahaan impactbiomedinc.com ing rentang 17.09.2024 - 20.11.2026

Ringkesan rincian data analitis Impact BioMedical, Inc. (IBO)

Analisis fundamental perusahaan:impactbiomedinc.com
Produk mawa merek Impact BioMedical

This metric serves as a key indicator of the issuer's solvency and operational viability. The metric tracks daily liquid asset balances, allowing for an assessment of the business's real margin of safety outside the scope of quarterly reports. By analyzing cash capital dynamics, an investor determines the company's ability to withstand market shocks. For Impact BioMedical Inc (IBO), this reserve is critically important when scaling costly oncological research. Sufficient liquidity ensures the stable development of the b2b patent licensing strategy.

Pesaing Impact BioMedical Inc (IBO)

Dana dhuwit perusahaan Haleon (HLN)|Volume dana dhuwit perusahaan Kenvue Inc. (KVUE)|Volume dana dhuwit perusahaan VRNA (veronapharma.com)|Sisa dhuwit perusahaan MENS|LGND: Dhuwit awis perusahaan|Sisa dhuwit perusahaan AMRX (Amneal Corp)|PRGO (Perrigo Company plc) - Dhuwit awis perusahaan|Alvotech - Sisa dhuwit perusahaan|Dhuwit awis perusahaan LQDA|Galapagos Genomics (GLPG) - Aset likuid perusahaan|Volume dana dhuwit perusahaan ANIP|Dhuwit awis perusahaan Afrezza MNKD|Dana dhuwit perusahaan Amphastar AMPH|Aset likuid perusahaan Pacira BioSciences (PCRX)|ARS Corp - Volume dana dhuwit perusahaan|TBPH: Dana dhuwit perusahaan|AQST: Volume dana dhuwit perusahaan|SCPH - Aset likuid perusahaan|TECX (Tectonic) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Tonix Pharmaceuticals Holding Corp. TNXP|Dana dhuwit perusahaan SXT Pharmaceuticals (SXTC)|Volume dana dhuwit perusahaan Eupraxia Pharmaceuticals Inc. (EPRX)|Dana dhuwit perusahaan BioHarvest Sciences BHST|EXOZ (Invizyne) - Total volume dana dhuwit perusahaan|ORMP: Dhuwit awis perusahaan|ENTX (Entera Bio Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|HYFT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan ABVC BioPharma Inc.|CPIX (cumberlandpharma.com) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan QNTM|Volume dana dhuwit perusahaan FGEN|Dhuwit awis perusahaan Telomir Pharmaceuticals TELO|Volume dana dhuwit perusahaan RANI (ranitherapeutics.com)|SNYR (Synergy CHC Corporation) - Total volume dana dhuwit perusahaan|RLYB - Dana dhuwit perusahaan|LEXX (Lexaria Bioscience Corp.) - Dhuwit awis lan setara dhuwit awis perusahaan|pulmatrix.com (PULM) - Dana dhuwit perusahaan|PTHL (Pheton) - Dana dhuwit perusahaan|Dana dhuwit perusahaan Aptorum|Cadangan dhuwit perusahaan Lyra Therapeutics Inc. LYRA|Volume dana dhuwit perusahaan TNFA|YCBD - Cadangan dhuwit perusahaan|PainReform Ltd. - Dhuwit awis perusahaan|CYTO (Auris Medical) - Total volume dana dhuwit perusahaan|LIPO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OPTN (OptiNose)|PIRS: Volume dana dhuwit perusahaan|Procaps Group S.A. (PROC) - Volume dana dhuwit perusahaan|PTPI (Petros Pharma) - Volume dana dhuwit perusahaan|QLI: Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan SLRN|TFFP (TFF Pharmaceuticals Inc.) - Sisa dhuwit perusahaan